Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Sponsor
Ain Shams University
Study ID
NCT06113900
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The aim of this study is to assess the safety and efficacy of SGLT2is among LN patients.

Key Dates

Start date
Dec 1, 2023
Status verified
Oct 2023
Primary completion
Dec 1, 2024
Completion
Jan 30, 2025

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Drug as Dapagliflozin 10 mg orally for 6 months is given
    25 lupus nephritis patients will receive SGLT2is as dapagliflozin 10mg beside there usual treatment of lupus for 6 months
  • No Intervention: On there conventional lupus nephritis treatment
    25 lupus nephritis patients didn't receive SGLT2i and continue on their conventional lupus nephritis treatment

Primary Outcome Measure

Renal Function Tests: [ Time Frame: 6 months ]

Central Contacts

Related Studies